Document is current
Any future updates will be listed below
-
Authors
Yasuma, Taro
Fujimoto, Hajime
D’Alessandro-Gabazza, Corina N.
Toda, Masaaki
Uemura, Mei
Nishihama, Kota
Takeshita, Atsuro
Fridman D’Alessandro, Valeria
Okano, Tomohito
Okano, Yuko
Tomaru, Atsushi
Anoh, Tomoko
Inoue, Chisa
Alhawsawi, Manal A. B.
Abdel-Hamid, Ahmed M. https://orcid.org/0000-0002-4557-2008
Leistikow, Kyle https://orcid.org/0000-0002-7719-4179
King, Michael R.
Ono, Ryoichi
Nosaka, Tetsuya https://orcid.org/0000-0002-0037-7049
Yamazaki, Hidetoshi
Fields, Christopher J. https://orcid.org/0000-0002-7749-5844
Mackie, Roderick I.
Mi, Xuenan https://orcid.org/0009-0001-5237-4712
Shukla, Diwakar https://orcid.org/0000-0003-4079-5381
Arrington, Justine https://orcid.org/0000-0003-1511-8805
Yano, Yutaka
Hataji, Osamu
Kobayashi, Tetsu https://orcid.org/0000-0003-4397-6137
Cann, Isaac https://orcid.org/0000-0003-0539-0119
Gabazza, Esteban C. https://orcid.org/0000-0001-5748-1499
-
Funding
Funding for this research was provided by:
MEXT | Japan Science and Technology Agency (JPMJFR2216)
Japan Society of Nutrition and Food Science (22K08280)
Takeda Science Foundation (2022, 2023)
Japan Association for Diabetes Education and Care Eli Lilly Japan Innovation Research Grant 2023
- License Information
-
More Information
Article History
Received: 13 January 2025
Accepted: 2 July 2025
First Online: 25 August 2025
Competing interests
: E.C.G. and Y.Y. have a patent on the TGFβ1 TG mice used in the present study. In addition, there is an invention disclosure by C.N.D.G., E.C.G. and I.C. on the corisin peptide and anticorisin mAtb developed for the treatment of organ fibrosis described in this study. The remaining authors declare no competing interests.
